NeuroOne Medical Technologies Corporation (NMTC)
| Market Cap | 40.13M |
| Revenue (ttm) | 11.72M |
| Net Income (ttm) | -6.83M |
| Shares Out | 8.45M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,332 |
| Open | 4.750 |
| Previous Close | 4.610 |
| Day's Range | 4.610 - 4.780 |
| 52-Week Range | 3.274 - 6.960 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 11.90 (+150.53%) |
| Earnings Date | May 12, 2026 |
About NMTC
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a ... [Read more]
Financial Performance
In fiscal year 2025, NMTC's revenue was $12.10 million, an increase of 250.35% compared to the previous year's $3.45 million. Losses were -$3.61 million, -70.73% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for NMTC stock is "Strong Buy." The 12-month stock price target is $11.9, which is an increase of 150.53% from the latest price.
News
NeuroOne Medical Technologies Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
A novel thin film electrode platform is driving growth in neurological device markets, with strong clinical outcomes, expanding partnerships, and a robust financial outlook. Key catalysts include new product launches, international expansion, and potential partnership deals in 2026.
NeuroOne Medical Technologies Transcript: Investor update
Four FDA-cleared devices target large neurological and pain markets, with strong partnerships and a unique thin-film platform driving growth. Fiscal 2026 revenue is guided at $10.5 million, with catalysts including new product launches, international expansion, and potential partnerships.
NeuroOne Medical Technologies Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose sequentially but was down year-over-year due to a prior large stocking order. Guidance for fiscal 2026 targets at least $10.5 million in sales, a 17% increase, with strong adoption of new products and ongoing strategic partnership discussions.
NeuroOne Medical Technologies Earnings Call Transcript: Q4 2025
Record product sales and improved margins drove a turnaround, with Q4 revenue up 907% year-over-year and net loss reduced by 71% for the year. FDA clearances, new product launches, and expanded partnerships position the company for continued growth in 2026.
NeuroOne Medical Technologies Transcript: Investor Update
Achieved $9.1M in product revenue and $3M in license revenue, expanded key partnerships, and advanced FDA-cleared products for epilepsy and pain management. Strong financial position supports growth, with new launches and strategic collaborations planned.
NeuroOne Medical Technologies Transcript: Small-Cap Virtual Conference
A next-generation electrode platform enables less invasive, combined diagnostic and therapeutic procedures for neurological disorders, supported by FDA-cleared products and strategic partnerships. Strong financials, expanding markets, and ongoing innovation position the company for significant growth and reduced investment risk.
NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025
EDEN PRAIRIE, Minn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgic...
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments
NeuroOne Medical Technologies Earnings Call Transcript: Q3 2025
Q3 FY2025 saw 105% product revenue growth, improved gross margins, and a narrowed net loss, driven by strong OneRF Ablation System performance and new product development. Guidance for FY2025 was reiterated, with funding secured through at least FY2026.
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: ...
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update
EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time
EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
Patent Strengthens Intellectual Property Portfolio Surrounding Neural Probe Technologies EDEN PRAIRIE, Minn., July 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)...
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
Patient Treated with OneRF ® Ablation System Previously Experienced up to 10 Seizures a Day EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NM...
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgica...
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical...
NeuroOne Medical Technologies Earnings Call Transcript: Q2 2025
Product revenue nearly doubled year-over-year to $4.7M in the first half, with gross margins more than doubling. Guidance for FY25 is $8–$10M in product revenue, driven by Zimmer Biomet, and the company is fully funded through FY26 after a successful capital raise.
NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%
Filed 510(k)Submission with FDA for OneRF ® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies
NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference
Eden Prairie, Minnesota--(Newsfile Corp. - May 5, 2025) - NeuroOne Medical (NASDAQ: NMTC), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2...
NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical...
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroO...
NeuroOne® Issues Letter to Shareholders
Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Cor...
NeuroOne® OneRF® Technology Success Story Featured on Fox News
Pediatric Patient Treated with OneRF® Ablation System Goes From Up to 10 Nightly Seizures to Zero EDEN PRAIRIE, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nas...
Nasdaq Dips 5%; NeuroOne Medical Technologies Shares Plummet
U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 1,100 points on Friday. Beijing unveiled a retaliatory 34% tariff on U.S. goods—mirroring the rate announced...